Promising combo tackles tough stomach cancer
NCT ID NCT01991379
First seen Dec 16, 2025 · Last updated May 06, 2026 · Updated 27 times
Summary
This study tests a new two-drug combination (MEK162 plus imatinib) for people with advanced gastrointestinal stromal tumor (GIST), a rare stomach or intestinal cancer. The goal is to find the safest dose and see if the combo shrinks tumors better than standard treatment. The study includes 75 adults whose cancer has either not been treated before or has stopped responding to imatinib alone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROINTESTINAL STROMAL TUMOR (GIST) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
Conditions
Explore the condition pages connected to this study.